(UroToday.com) With the emergence of multiple active treatment options in renal cell carcinoma (RCC), predictive biomarkers for optimal treatment selection are lacking. Gene expression data from IMmotion1511 and Javelin Renal 1012 clinical trials generated anti-angiogenic and immune signatures that warrant further validation. At the Poster Highlights: Renal Cell Cancer – Gene Signatures Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Pedro Barata and colleagues presented results of their study describing the genomic and gene expression profiles in a multi-institutional database of patients with clear cell RCC, and its association with other biomarkers of interest.